Skye Bioscience Inc. (SKYE)
| Bid | 3.21 |
| Market Cap | 109.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.65M |
| EPS (ttm) | -1.06 |
| PE Ratio (ttm) | -3.33 |
| Forward PE | -2.49 |
| Analyst | Buy |
| Ask | 3.7 |
| Volume | 370,276 |
| Avg. Volume (20D) | 911,148 |
| Open | 3.31 |
| Previous Close | 3.27 |
| Day's Range | 3.22 - 3.55 |
| 52-Week Range | 1.14 - 7.47 |
| Beta | 2.21 |
About SKYE
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab DosingSkye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Buys Shares of 13,546 Skye Bioscience, Inc. (NASDAQ:SKYE)Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exc...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Takes Position in Skye Bioscience, Inc. (NASDAQ:SKYE)Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SE...
2 months ago · proactiveinvestors.co.uk
Arecor shares jump 10% on obesity drug partnership with Skye BioscienceShares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-st...
2 months ago · proactiveinvestors.co.uk
Arecor partners with Skye Bioscience to improve formulation of obesity drugArecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experim...